Table 1.

Relative survival rates of pancreatic neuroendocrine neoplasm patients during the periods of 1987–1996, 1997–2006, and 2007–2016 at nine SEER sites. Data are represented as mean ± standard error of the mean, with number of patients in parentheses.

Age group	Decade
	1987–1996	1997–2006	2007–2016
12-Mo RS
All	73.0 ± 2.1 (474)	73.7 ± 1.6 (833)	82.6 ± 0.9 (2159)∗∗∗∗
0–44	85.3 ± 3.5 (101)	88.4 ± 2.7 (146)	92.7 ± 1.6 (301)
45–59	83.8 ± 3.1 (149)	82.3 ± 2.2 (303)	85.1 ± 1.4 (706)
60–74	63.8 ± 3.9 (162)	66.7 ± 3.0 (264)	81.2 ± 1.5 (809)∗∗∗∗
75+	50.3 ± 6.8 (62)	48.7 ± 4.8 (120)	72.0 ± 2.8 (343)∗∗∗∗
60-Mo RS
All	41.6 ± 2.4 (474)	44.3 ± 1.8 (833)	63.4 ± 1.5 (2159)∗∗∗∗
0–44	50.0 ± 5.0 (101)	63.1 ± 4.1 (146)∗	74.5 ± 3.3 (301)∗
45–59	52.8 ± 4.2 (149)	47.0 ± 3.0 (303)	65.8 ± 2.3 (706)∗∗∗∗
60–74	34.3 ± 4.1 (162)	40.6 ± 3.3 (264)	62.9 ± 2.4 (809)∗∗∗∗
75+	16.7 ± 6.0 (62)	20.7 ± 4.5 (120)	48.4 ± 5.0 (343)∗∗
120-Mo RS
All	27.5 ± 2.3 (474)	33.6 ± 1.8 (833)∗	51.1 ± 2.8 (2159)∗∗∗
0–44	31.9 ± 4.8 (101)	52.6 ± 4.3 (146)∗∗	65.2 ± 5.2 (301)
45–59	33.8 ± 4.2 (149)	33.4 ± 2.9 (303)	55.9 ± 5.6 (706)∗
60–74	23.1 ± 4.0 (162)	31.1 ± 3.4 (264)	47.4 ± 4.9 (809)
75+	13.0 ± 7.3 (62)	13.5 ± 4.6 (120)	22.7 ± 9.0 (343)

Abbreviations: Mo, month; RS, relative survival; SEM, standard error of the mean. ^∗p < 0.05, ^∗∗p < 0.001, ^∗∗∗p < 0.0001, ^∗∗∗∗p < 0.00001 for comparisons with the preceding decade.